Levi & Korsinsky, LLP announces that a RETA class action lawsuit has been filed on behalf of investors who purchased Reata Pharmaceuticals, Inc. (RETA) securities and/or put options between November 9, 2020 and December 8, 2021. For more on the RETA lawsuit please contact us today.
According to the Reata Pharmaceuticals, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration had raised concerns regarding the validity of the clinical study designed to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome; (2) as a result, there was a material risk that Reata’s New Drug Application would not be approved; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Reata Pharmaceuticals, Inc. you have until February 18, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.